longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

WHYY

002107

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 33.48, below the reasonable range, cheaper than 92.06% of the time in the past 3 years, and the industry ranks 82/221, the industry Median 23.14.

33.48xP/E
¥6.88Stock price
¥0.21Earnings per share
33.48xP/E
Stock price¥6.88Earnings per share¥0.21

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
51.83x
Typical range
40.96x–75.50x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.14x
020406080

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.14x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
600276SHHengrui Pharma
37.07x17.99%¥286.40B
600436SHZZPZH
39.58x1.29%¥71.61B
002422SZKELUN PHARMA
35.99x15.33%¥65.83B
600085SHTRT
33.32x4.81%¥32.33B
600329SHDRTG
31.44x51.62%¥26.67B
000739SZAPELOA
30.91x23.79%¥26.27B
600521SHHuahaipharm
37.25x305.56%¥23.39B
002262SZNHWA
20.11x14.76%¥22.07B
600664SHHPGC
35.89x71.43%¥18.39B
603456SHJiuzhou Pharma
22.38x12.93%¥13.24B
603707SHNKF
25.03x11.11%¥12.09B
002019SZYifan Pharmaceutical
37.33x12.12%¥11.32B
600420SHSHYNDEC
20.47x--¥11.16B
600572SHCONBA
22.00x--¥10.97B
002626SZKingdomway
38.15x56.36%¥10.02B
300357SZWolwo Pharma
23.90x18.88%¥9.97B
688076SHSinopep
37.70x91.51%¥8.95B
002332SZXJZY
22.25x5.56%¥8.59B
688513SHEASTON BIOPHARMACEUTICALS
30.28x0.00%¥8.39B
002550SZQianhong Bio-pharma
27.86x--¥8.18B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.